Public Profile

Astellas

Astellas Pharma Inc., commonly referred to as Astellas, is a leading global pharmaceutical company headquartered in Tokyo, Japan. Founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in innovative medicines, Astellas focuses on areas such as oncology, urology, immunology, and neuroscience. The company is renowned for its commitment to research and development, which has led to the introduction of unique therapies that address unmet medical needs. Astellas has achieved notable market recognition, consistently ranking among the top pharmaceutical firms worldwide, thanks to its dedication to improving patient outcomes and advancing healthcare solutions.

DitchCarbon Score

How does Astellas's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

50

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Astellas's score of 50 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.

84%

Let us know if this data was useful to you

Astellas's reported carbon emissions

In 2023, Astellas Pharma Inc. reported significant greenhouse gas emissions, totalling approximately 1,121,350,000 kg CO2e. This figure includes 59,203,000 kg CO2e from Scope 1 emissions, 63,047,000 kg CO2e from Scope 2 emissions, and a substantial 1,121,350,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its carbon footprint, aiming for a 63% reduction in absolute Scope 1 and 2 emissions by fiscal year 2030, using 2015 as the baseline year. Additionally, Astellas is committed to reducing its Scope 3 emissions by 37.5% per unit of revenue by the same deadline. Astellas has also pledged to achieve net-zero greenhouse gas emissions across all scopes by 2050, reinforcing its commitment to sustainability and climate action. The company’s initiatives align with industry standards and reflect a proactive approach to addressing climate change, demonstrating a clear pathway towards significant emissions reductions in the coming years.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20052008201120122013201420152016201820192020202120222023
Scope 1
108,000,000
000,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
-
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
-
000,000,000
00,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
000,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
00,000,000
-
-
-
-
0,000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Astellas's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Astellas is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Astellas is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Nanjing MeiRui Pharma Co., Ltd.

CN
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Best Medical International, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Bayer Pharma AG

DE
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Hospira

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Allergan, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Tty Biopharm

TW
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers